News

Merck Signs Nearly $500 Million Licensing Deal With Austria-Based Cyprumed For Tablet-Based Peptide Delivery
Merck signs deal with Austria's Cyprumed to develop oral peptide therapies, potentially paying up to $493 million for access ...
Gastrointestinal Stromal Tumor Market To Grow Rapidly During The Study Period (2020–2034) Owing To The Launch Of Emerging Therapies | Delveinsight
According to DelveInsight's analysis, the market for GIST is anticipated to increase during the forecast period (2025–2034), owing to the launch of e ...